| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b21f650fc35b3e1947103e89adb06f3f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D407-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-82 |
| filingDate |
2012-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_345cc9f8faeeae1ee6bec7304abb5a18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15ab02ede513dd210331590cf696fc04 |
| publicationDate |
2014-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014113897-A1 |
| titleOfInvention |
Compositions and methods for modulating the activity of epstein-barr nuclear antigen 1 |
| abstract |
The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R 7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10981867-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016183534-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107848964-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11242317-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11242338-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10442763-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10421718-B2 |
| priorityDate |
2011-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |